These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 24836726)

  • 21. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860
    [No Abstract]   [Full Text] [Related]  

  • 23. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
    Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
    Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of RAAS-natriuretic peptides in the treatment of HF: Old guys and newcomers.
    Mollace V; Gliozzi M; Capuano A; Rossi F
    Int J Cardiol; 2017 Jan; 226():126-131. PubMed ID: 27075034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin receptor--neprilysin inhibiton (ARNI)--a novel therapeutic concept for management of hypertension and heart failure.
    Kjeldsen SE; Hedner T; Narkiewicz K; Oparil S
    Blood Press; 2012 Dec; 21(6):329-30. PubMed ID: 23210746
    [No Abstract]   [Full Text] [Related]  

  • 28. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure.
    Martin FL; Stevens TL; Cataliotti A; Schirger JA; Borgeson DD; Redfield MM; Luchner A; Burnett JC
    Kidney Int; 2005 May; 67(5):1723-30. PubMed ID: 15840018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?
    Malek V; Gaikwad AB
    Biomed Pharmacother; 2017 Jun; 90():752-759. PubMed ID: 28419972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
    Bavishi C; Messerli FH; Kadosh B; Ruilope LM; Kario K
    Eur Heart J; 2015 Aug; 36(30):1967-73. PubMed ID: 25898846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vasopeptidase inhibitors. Clinical implications of a new class of drugs].
    Quaschning T; Corti R; Ruschitzka FT; Noll G; Lüscher TF
    Dtsch Med Wochenschr; 2000 Apr; 125(16):499-503. PubMed ID: 10819011
    [No Abstract]   [Full Text] [Related]  

  • 35. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction.
    Quaschning T; Galle J; Wanner C
    Kidney Int Suppl; 2003 May; (84):S54-7. PubMed ID: 12694309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasopeptidase inhibition: a double-edged sword?
    Campbell DJ
    Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.
    Chen HH; Cataliotti A; Burnett JC
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S15-21. PubMed ID: 11716801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.